Adenosine receptors as therapeutic targets

被引:1183
作者
Jacobson, KA [1 ]
Gao, ZG [1 ]
机构
[1] NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1038/nrd1983
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
引用
收藏
页码:247 / 264
页数:18
相关论文
共 210 条
[1]  
Abbracchio MP, 1995, MOL PHARMACOL, V48, P1038
[2]   Aggravated brain damage after hypoxic ischemia in immature adenosine A2A knockout mice [J].
Ådén, U ;
Halldner, L ;
Lagercrantz, H ;
Dalmau, I ;
Ledent, C ;
Fredholm, BB .
STROKE, 2003, 34 (03) :739-744
[3]   Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist [J].
Aoyama, S ;
Kase, H ;
Borrelli, E .
JOURNAL OF NEUROSCIENCE, 2000, 20 (15) :5848-5852
[4]   Prospective study of caffeine consumption and risk of Parkinson's disease in men and women [J].
Ascherio, A ;
Zhang, SMM ;
Hernán, MA ;
Kawachi, I ;
Colditz, GA ;
Speizer, FE ;
Willett, WC .
ANNALS OF NEUROLOGY, 2001, 50 (01) :56-63
[5]  
Auchampach JA, 1997, CIRC RES, V80, P800
[6]   Canine mast cell adenosine receptors: Cloning and expression of the A(3) receptor and evidence that degranulation is mediated by the A(2B) receptor [J].
Auchampach, JA ;
Jin, XW ;
Wan, TC ;
Caughey, GH ;
Linden, J .
MOLECULAR PHARMACOLOGY, 1997, 52 (05) :846-860
[7]   Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs [J].
Auchampach, JA ;
Jin, XW ;
Moore, J ;
Wan, TC ;
Kreckler, LM ;
Ge, ZD ;
Narayanan, J ;
Whalley, E ;
Kiesman, W ;
Ticho, B ;
Smits, G ;
Gross, GJ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03) :846-856
[8]  
Avila MY, 2002, INVEST OPHTH VIS SCI, V43, P3021
[9]  
Baharav E, 2005, J RHEUMATOL, V32, P469
[10]   Adenosine A2A receptor antagonist treatment of Parkinson's disease [J].
Bara-Jimenez, W ;
Sherzai, A ;
Dimitrova, T ;
Favit, A ;
Bibbiani, F ;
Gillespie, M ;
Morris, MJ ;
Mouradian, MM ;
Chase, TN .
NEUROLOGY, 2003, 61 (03) :293-296